Unity Biotechnology, Inc. (0YC0.L)
USD 1.02
(-1.45%)
USD 1.02
(-1.45%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 26.99 Million USD | -43.01% |
| 2022 | 47.35 Million USD | -8.15% |
| 2021 | 51.55 Million USD | -12.58% |
| 2020 | 58.97 Million USD | 130957.78% |
| 2019 | 45 Thousand USD | -63.71% |
| 2018 | 124 Thousand USD | -38.61% |
| 2017 | 202 Thousand USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 22.6 Million USD | -16.24% |
| 2024 Q3 | 20.69 Million USD | -4.44% |
| 2024 Q2 | 21.65 Million USD | -4.19% |
| 2023 Q4 | 26.99 Million USD | 10.47% |
| 2023 Q1 | 46.83 Million USD | -1.11% |
| 2023 FY | 26.99 Million USD | -43.01% |
| 2023 Q2 | 43.08 Million USD | -8.0% |
| 2023 Q3 | 24.43 Million USD | -43.29% |
| 2022 Q1 | 48.71 Million USD | -5.52% |
| 2022 FY | 47.35 Million USD | -8.15% |
| 2022 Q4 | 47.35 Million USD | -0.99% |
| 2022 Q3 | 47.83 Million USD | -1.03% |
| 2022 Q2 | 48.33 Million USD | -0.78% |
| 2021 Q1 | 57.96 Million USD | -1.72% |
| 2021 Q4 | 51.55 Million USD | -7.77% |
| 2021 Q2 | 56.92 Million USD | -1.79% |
| 2021 FY | 51.55 Million USD | -12.58% |
| 2021 Q3 | 55.89 Million USD | -1.81% |
| 2020 FY | 58.97 Million USD | 130957.78% |
| 2020 Q2 | 36.77 Million USD | -2.95% |
| 2020 Q1 | 37.88 Million USD | 0.0% |
| 2020 Q3 | 59.94 Million USD | 63.03% |
| 2020 Q4 | 58.97 Million USD | -1.62% |
| 2019 FY | 45 Thousand USD | -63.71% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | -100.0% |
| 2019 Q2 | 7000.00 USD | -73.08% |
| 2019 Q1 | 26 Thousand USD | -42.22% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 124 Thousand USD | -38.61% |
| 2018 Q4 | 45 Thousand USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 FY | 202 Thousand USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | 26.128% |
| Dynavax Technologies Corporation | 256.91 Million USD | 89.495% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 35.006% |
| Perrigo Company plc | 4.07 Billion USD | 99.337% |
| Illumina, Inc. | 2.26 Billion USD | 98.807% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.923% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -2599.0% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.718% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.81% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 84.466% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.001% |
| Waters Corporation | 2.35 Billion USD | 98.854% |
| Biogen Inc. | 7.33 Billion USD | 99.632% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 29.168% |
| Evolus, Inc. | 126.54 Million USD | 78.672% |
| Adicet Bio, Inc. | 17.7 Million USD | -52.46% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 37.475% |
| bluebird bio, Inc. | 330.32 Million USD | 91.829% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 95.011% |
| FibroGen, Inc. | 170.45 Million USD | 84.166% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.013% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -29.236% |
| Homology Medicines, Inc. | 44.05 Million USD | 38.734% |
| Geron Corporation | 85.89 Million USD | 68.579% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 98.874% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 93.936% |
| Myriad Genetics, Inc. | 145 Million USD | 81.386% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -2042.063% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 76.601% |
| Zoetis Inc. | 6.8 Billion USD | 99.603% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -513.13% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 98.755% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 97.62% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 96.661% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 25.694% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 98.143% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 53.363% |
| Verastem, Inc. | 41.55 Million USD | 35.053% |
| Nektar Therapeutics | 230.4 Million USD | 88.286% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 85.518% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -778.009% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 98.068% |
| OPKO Health, Inc. | 326.56 Million USD | 91.735% |
| Exelixis, Inc. | 189.94 Million USD | 85.791% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 93.7% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -17774.172% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 80.5% |
| Imunon, Inc. | 1.13 Million USD | -2269.013% |
| Blueprint Medicines Corporation | 774.12 Million USD | 96.513% |
| Insmed Incorporated | 1.2 Billion USD | 97.758% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 98.2% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 52.639% |
| TG Therapeutics, Inc. | 110.79 Million USD | 75.64% |
| Incyte Corporation | 38.28 Million USD | 29.506% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 96.924% |